Clinical Trial

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal…

2 weeks ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY…

2 weeks ago

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist…

2 weeks ago

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of…

2 weeks ago

NextCure Announces Acceptance of IND Application for LNCB74

LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024…

2 weeks ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)…

2 weeks ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and…

2 weeks ago

Zero Candida Receives South African Patent for its ZC- 01 device

Announces IP plans to obtain a worldwide patent portfolio in 2025 VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- Zero Candida…

2 weeks ago

Phastar Scoops Prestigious 2024 Scrip Award

LONDON and DURHAM, N.C., Dec. 9, 2024 /PRNewswire/ -- Phastar, a global specialist biometrics contract research organization (CRO), has won the…

2 weeks ago